TYK Medicines, Inc
HKSE: 2410.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Yusheng Wu
- Employees
- 153
- Headquarters
- Huzhou, China
- IPO year
- 2024
- Market cap
- HK$3.7B
- Website
- https://www.tykmedicines.com
Loading 2410…
Loading profile data…Frequently asked questions about 2410
What does TYK Medicines, Inc (2410.HK) do?
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment o...
Where does 2410.HK trade?
TYK Medicines, Inc (2410.HK) trades on the Hong Kong Stock Exchange.
What sector is 2410.HK in?
TYK Medicines, Inc (2410.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of TYK Medicines, Inc?
Yusheng Wu is the chief executive officer of TYK Medicines, Inc (2410.HK).
Where is TYK Medicines, Inc headquartered?
TYK Medicines, Inc is headquartered in China.
Does 2410.HK pay a dividend?
TYK Medicines, Inc (2410.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2410.HK go public?
TYK Medicines, Inc (2410.HK) completed its initial public offering in 2024.